Clinical trials
Phase 3 Carcinoma, Non-Small-Cell Lung trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
154 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 3 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 4 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 10 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 10 |
| 2019 | 10 |
| 2020 | 13 |
| 2021 | 8 |
| 2022 | 12 |
| 2023 | 14 |
| 2024 | 19 |
| 2025 | 14 |
| 2026 | 10 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 51 |
| Completed | 47 |
| Recruiting | 37 |
| Terminated | 18 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 27 |
| Merck Sharp & Dohme LLC | 27 |
| Bristol-Myers Squibb | 13 |
| Hoffmann-La Roche | 13 |
| Pfizer | 9 |
| Novartis Pharmaceuticals | 7 |
| Eli Lilly and Company | 6 |
| Daiichi Sankyo | 4 |
| EMD Serono Research & Development Institute, Inc. | 4 |
| Janssen Research & Development, LLC | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 154 |
| Lung Neoplasms | 26 |
| Carcinoma | 11 |
| Neoplasm Metastasis | 9 |
| Neoplasms | 6 |
| Lung Diseases | 5 |
| Adenocarcinoma of Lung | 4 |
| Adenocarcinoma | 3 |
| Respiratory Tract Neoplasms | 3 |
| Bronchial Neoplasms | 2 |
Trials
Showing 1 to 25 of 154. Each trial links to its page on Pharma Observatory.
54 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.